Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrenkel Topping Regulatory News (FEN)

Share Price Information for Frenkel Topping (FEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 53.50
Bid: 53.00
Ask: 54.00
Change: 0.00 (0.00%)
Spread: 1.00 (1.887%)
Open: 53.50
High: 53.50
Low: 53.50
Prev. Close: 53.50
FEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

29 Sep 2023 07:00

RNS Number : 0821O
Frenkel Topping Group PLC
29 September 2023
 

29th September 2023

 

 

Frenkel Topping Group plc

("Frenkel Topping", or "the Group")

 

Interim Results

 

Frenkel Topping (AIM: FEN), a specialist financial and professional services firm operating within the personal injury and clinical negligence marketplace (PI and Clin Neg), is pleased to announce its interim results for the six months ended 30 June 2023.

 

Financial Highlights

 

H1 2023*

(£m)

H1 2022*

(£m)

% change

FY2022

Full year (£m)

Revenue

16.0

11.1

44%

24.8

Recurring revenue

5.9

5.4

9%

11.0

Gross profit

6.6

5.0

32%

11.1

EBITDA**

3.5

2.7

30%

6.1

Profit attributable to shareholders

1.7

0.9

89%

1.7

EPS (basic)

1.4 pence

0.8 pence

75%

1.5 pence

Cash generated from operating activities

1.5

0.6

150%

0.7

Cash at period end

4.9

1.8

272%

5.0

AUM

1,261

1,155

9%

1,187

Assets on a discretionary mandate

761

667

14%

715

 

*Unaudited

**EBITDA before share based compensation, acquisition strategy, integration and reorganisation costs

 

Operational Highlights

 

· Results for first six months in line with management expectations

· AUM resilient despite challenging market conditions demonstrating the differentiated and conservative way the Group manages its clients' assets

· Client retention rate remains high at 99%

· Acquisitions made in Q4 2022 bedded in and performing well

· Cardinal Management Ltd ("Cardinal"), a milestone acquisition during 2022, has added two new major trauma centres to its portfolio

· Continued delivery of the "Working in Partnership" programme - aligning with top law firms, adding Serious Injury Law and Lime Solicitors to the growing number of firms who we have joint ventures with

· A healthy pipeline of AUM for the second half of the year, a traditionally stronger half, to underpin management's expectations for the full year outturn

 

Delivery of strategy with a strong start to the second half

 

· Continued execution of acquisition strategy, with a number of opportunities being evaluated and the businesses acquired to date showing positive contribution to the Group

· Acquisition strategy has built one of the largest players in the pre-settlement professional services market for Personal Injury ("PI") and Clinical Negligence ("Clin Neg")

· Entering second half of the year carrying momentum from H1 with services revenue performing particularly well from Somek and Associates, Bidwell Henderson Cost Consultants (BH) and Forth Associates.

 

 

For further information: 

Frenkel Topping Group plc

www.frenkeltoppinggroup.co.uk

Richard Fraser, Chief Executive Officer

Tel: 0161 886 8000

Cavendish Capital Markets Limited (Nominated Advisor & Broker)

Tel: 020 7220 0500

Carl Holmes/Abigail Kelly (Corporate Finance)

Tim Redfern / Charlotte Sutcliffe (ECM)

 

CEO statement - Richard Fraser:

We are pleased with our performance in the first half of FY2023 and the momentum we are carrying into the second half of the year. Despite the backdrop of economic headwinds and market volatility, our team has shown remarkable resilience and focus, delivering a robust set of results for the first six months of the year.

 

We constantly strive to deliver the best outcomes for our clients. In response to rising interest rates and subsequent returns available on cash, our Investment Management business, Ascencia, has recently launched a cash solution to add to our existing portfolio of products focused on protecting our clients' assets, thus adding to our range of recurring income streams. The solution has been particularly well received by professional intermediaries and clients. 

 

Further, Ascencia has continued to outperform in its core risk rated investment strategies, with returns being ahead of their respective Private Client ARC indices. Ascencia's IP Growth 4 returned 1.24% compared to ARC Sterling Balanced Asset PCI of 1.01% and Ascencia's IP Growth 3 returned 0.95% compared to ARC Sterling Cautious PCI of 0.09%.

 

Our client retention rate, a critical KPI of the Group, remains exceptionally high at 99%, a testament to the trust and confidence our clients place in us.

 

The successful integration of our acquisitions has not only diversified our income streams but also strengthened our position in the personal injury and clinical negligence sectors. We continue to pursue future acquisition opportunities within the space that will further add to our full market offering.

 

The Company's group businesses have enjoyed real momentum in the period with Cardinal adding two new sites to its Major Trauma Centre portfolio in recent months both John Radcliffe Hospital, run by Oxford University Hospitals NHS Foundation Trust, and Alder Hey Children's Hospital opting to join Cardinal after a competitive tender process.

 

Somek and Associates (Somek), Bidwell Henderson Cost Consultants (BH) and Forth Associates (Forths) have especially contributed to the service revenue performance during the first six month of the year. This is primarily due to the successful execution of our people plan, specifically increasing the number of Experts in Somek, the success of the BH training academy and recruitment programme, and staff progression in Forths, all underpinned by the overall execution of our strategy to be the 'go to' provider of professional services within PI and Clin Neg.

 

 

Our marketplace continues to present significant opportunity for growth with c£1.2bn of personal injury awards related to motor accident claims alone paid out in H1 2023. In addition, we have noticed a tightening of court deadlines within the industry which presents opportunities across our full service offering which, in turn, we expect should drive faster settlement of damages moving forward.

 

As we look ahead, we are excited about the potential of AI to drive efficiencies and are committed to delivering value to our shareholders and clients alike. It's not just about numbers; it's about making a meaningful difference in the lives of those who have been through life-altering experiences. That's what keeps us motivated every single day.

 

Outlook

 

The Group has entered the second half of the year carrying real momentum from H1, benefiting from the diversification of revenue and encouraging growth in transactional revenue. We expect financial markets to remain challenging, which will continue to moderately impact AUM growth and consequently the Company's recurring revenue. However, the Board maintains its confidence in the full year outturn which is tracking in line with management's expectation.

 

CFO statement - Elaine Cullen-Grant:

 

We are pleased to report such a strong set of results against the backdrop of a challenging economic climate and furthermore to have been able to grow our recurring revenue in the first half by 9% to £5.9m (H1 22 - £5.5m) . 

 

The acquisitions made in recent years have further strengthened our position in these challenging times by broadening our income streams and helping to contribute to an overall 44% growth in revenue to £16.0m (H1 22: £11.1m).

 

By their nature the margin profile within our transactional businesses is a little lower than our financial businesses, however we are delighted that we continue to grow EBITDA across the Group.

 

Our acquisition strategy is focused on profitable and growing businesses. Evidence of the success of this strategy can be seen within our Costs businesses, Partners in Costs, A&M Bacon and BH, acquired during 2021, which have increased their EBITDA contribution from £0.6m in the first half of last year to £1.1m in the same period this year.

 

Following the increase in share capital with our fundraise in 2022, it is pleasing that we have been able to increase our basic earnings per share by 74% to 1.4 pence for H1 23 (H1 22: 0.8 pence), coming close to delivering the same earnings per share as we did in the full year 2022 (FY22: 1.5 pence) in just six months.

 

Whilst the transactional businesses do have a greater working capital requirement when compared with the financial businesses, we are pleased that even the with the 44% increase in revenue, cash generated from operating activities has improved by 150%. This is both a reflection on the Group's focus on cash conversion and evidence of the strength of the recoverability of our debtor book. This has helped contribute to our strong balance sheet and cash position of £4.9m (H1 22 1.8m)

 

Change of Name of Nominated Adviser and Broker

 

The Company also announces that its Nominated Adviser and Broker has changed its name to Cavendish Capital Markets Limited following completion of its own corporate merger.

 

 

 

 

 

Frenkel Topping Group plc

6 Months

6 Months

Year

Group income statement for the period:

 

 ended

30-Jun-23

 ended

30-Jun-22

ended

31-Dec- 22

Unaudited

Unaudited

Audited

Notes

£'000

£'000

£'000

REVENUE

16,042

11,110

24,850

Direct staff costs

(9,436)

(6,068)

(13,717)

 

Gross Profit

6,606

5,042

11,133

Administrative expenses

2

(3,996)

(3,544)

(8,230)

Underlying profit from operations

3,200

2,422

5,492

- share based compensation

(314)

(349)

(660)

- acquisition strategy, integration and reorganisation costs

(276)

(575)

(1,929)

PROFIT FROM OPERATIONS

2,610

1,498

2,903

Finance and other income/ (fair value losses on investments)

4

(9)

(7)

Finance costs

3

(186)

(205)

(477)

PROFIT BEFORE TAX

2,428

1,284

2,419

Income tax expense

(628)

(309)

(570)

PROFIT FOR THE PERIOD

1,800

975

1,849

Gains on property revaluation arising net of tax

-

-

127

TOTAL COMPREHENSIVE INCOME FOR THE PERIOD

1,800

975

1,976

PROFIT ATTRIBUTABLE TO:

Owners of parent undertakings

1,680

881

1,652

Non-controlling interest

120

94

197

TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO:

Owners of parent undertakings

1,680

881

1,779

Non-controlling interest

120

94

197

0.

0.

Earnings per share - basic (pence)

1.4

0.8

1.5

Earnings per share - diluted (pence)

1.3

0.8

1.4

 

The results for the period are derived from continuing activities.

 

 

 

Frenkel Topping Group plc

Group Statement of Financial Position as at:

30-Jun-23

30-Jun-22

31-Dec-22

Unaudited

Unaudited

Audited

£'000

£'000

£'000

ASSETS

NON CURRENT ASSETS

Goodwill and other intangibles

29,250

24,088

29,579

Plant, property and equipment

2,717

2,457

2,834

Loans receivable

168

166

162

32,135

26,711

32,575

CURRENT ASSETS

Accrued income

4,903

3,102

4,072

Trade receivables

11,086

7,693

10,661

Other receivables

1,146

858

749

Investments

101

99

100

Cash at bank and in hand

4,866

1,761

4,986

22,102

13,513

20,568

TOTAL ASSETS

54,237

40,224

53,143

EQUITY AND LIABILITIES

EQUITY

Share capital

637

566

637

Share premium

22,705

13,140

22,705

Merger reserve

6,245

6,245

6,245

Revaluation reserve

479

352

479

Own share reserve

(2,134)

(2,315)

(2,210)

Other reserve

(341)

(341)

(341)

Retained earnings

14,149

12,965

12,296

Equity attributable to owners of the parent company

41,740

30,612

39,811

Non-controlling interests

238

180

283

TOTAL EQUITY

41,978

30,792

40,094

CURRENT LIABILITIES

Current taxation

1,075

871

760

Trade and other payables

7,375

4,508

7,680

8,450

5,379

8,440

LONG TERM LIABILITIES

3,809

4,053

4,609

TOTAL EQUITY AND LIABILITIES

54,237

40,224

53,143

 

 

 

 

Frenkel Topping Group plc

6 Months

6 Months

Year

Group Cash Flow Statement

For the period:

 ended

30-Jun-23

 ended

30-Jun-22

ended

31-Dec- 22

Unaudited

Unaudited

Audited

£'000

£'000

£'000

Profit before tax

2,428

1,284

2,419

Adjustments to reconcile profit for the period to cash generated from operating activities:

Finance income/loss

(4)

9

7

Finance costs

186

205

477

Share based compensation

242

349

480

Depreciation

304

238

574

(Increase)/decrease in accrued income,

trade and other receivables

(1,660)

(1,015)

(2,205)

(Decrease)/increase in trade and other payables

405

(101)

(95)

Cash generated from operations

1,901

969

1,657

Income Tax paid

(363)

(323)

(999)

Cash generated from operating activities

1,538

646

658

Investing Activities

Acquisition of plant, property and equipment

(148)

(163)

(240)

Acquisition of subsidiaries

(1,100)

(8,084)

(13,478)

Cash acquired on acquisition of subsidiaries

-

1,033

1,992

Loans advanced

-

(21)

(22)

Cash (used) / generated in investing activities

(1,248)

(7,235)

(11,748)

Financing activities

Shares issued (net of costs)

-

-

9,637

Exercise of share options

1

-

1

Dividend paid

(165)

(110)

(1,771)

Repayment of borrowing

(36)

-

(2)

Interest received

4

-

-

Interest element of lease payments

(17)

(17)

(36)

Principal element of lease payments

(197)

(141)

(368)

Other interest paid and FX losses

-

-

(3)

Cash used in financing

(410)

(268)

7,458

(Decrease)/ increase in cash

 

(120)

(6,857)

(3,632)

Opening cash

4,986

8,618

8,618

Closing cash

4,866

1,761

4,986

 

Closing Cash and Cash Equivalents

Cash

4,866

1,761

4,986

Cash equivalents

101

99

100

Closing cash and cash equivalents

4,967

1,860

5,086

 

Cash equivalents are held in liquid investments.

 

 

 

Notes to the Interim Financial Statements

 

 

1. Revenue and Segmental Reporting

 

All of the Group's revenue arises from activities within the UK.

Revenue arising from recurring and non-recurring sources is as follows:

 

6 Months

6 Months

Year

 ended

30-Jun-23

ended

30-Jun-22

ended

31-Dec- 22

£'000

£'000

£'000

 

Recurring

5,899

5,424

11,045

Non-recurring

10,143

5,686

13,805

 _______

 _______

 _______

Total revenue

16,042

11,110

24,850

 _______

 _______

 _______

 

Operating Segments

 

The Group's chief operating decision maker is deemed to be the CEO. The CEO has identified the following operating segments:

 

Financial Services

This segment includes our independent financial advisory, discretionary fund management and financial services businesses.

 

Costs Law

This segment includes each of our costs law services businesses.

 

Other Professional Services

This segment includes our major trauma signposting, forensic accountancy, care and case management and medico-legal reporting businesses.

 

Central Services

This is predominantly a cost centre for managing Group related activities or other costs not specifically related to a product.

 

6 Months ended June 2023

Financial services

CostsLaw

Other Professional Services

Central Services

Total

£'000

£'000

£'000

£'000

£'000

Revenue

6,305

4,162

5,550

25

16,042

Adjusted EBITDA

1,924

1,056

1,437

(888)

3,529

 

 

 

6 Months ended June 2022

Financial services

CostsLaw

Other Professional Services

Central Services

Total

£'000

£'000

£'000

£'000

£'000

Revenue

5,846

3,154

2,110

-

11,110

Adjusted EBITDA

2,124

631

693

(788)

2,660

 

 

 

Year ended December 2022

Financial services

CostsLaw

Other Professional Services

Central Services

Total

£'000

£'000

£'000

£'000

£'000

Revenue

11,792

7,057

6,001

-

24,850

Adjusted EBITDA

4,302

1,721

1,763

(1,732)

6,054

 

 

2. Administrative Expenses

 

The following table analyses the nature of expenses:

 

6 Months

6 Months

Year

 ended

30-Jun-23

ended

30-Jun-22

ended

31-Dec- 22

£'000

£'000

£'000

Depreciation

329

238

574

Share based compensation

314

349

660

Acquisition strategy, integration and reorganisation costs

276

575

1929

Other administrative expenses

3,077

2,382

5,067

Total Other administrative expenses

3,996

3,544

8,230

 

 

3. Interest and similar items

 

6 Months

6 Months

Year

 ended

30-Jun-23

ended

30-Jun-22

ended

31-Dec- 22

£'000

£'000

£'000

Interest on lease liabilities

17

17

36

Loan and other interest charges

-

-

3

Unwinding discount - deferred consideration

169

188

438

Total finance costs

186

205

477

 

 

 

 

About Frenkel Topping Group

The Frenkel Topping Group of companies specialises in providing financial advice and asset protection services to clients at times of financial vulnerability, with particular expertise in the field of personal injury (PI) and clinical negligence (CN).

For more than 30 years the Group has worked with legal professionals and injured clients themselves to provide pre-settlement, at-settlement and post-settlement services to help achieve the best long-term outcomes for clients after injury. It boasts a client retention rate of 99%.

Frenkel Topping Group is focused on consolidating the fragmented PI and CN space in order to provide the most comprehensive suite of services to clients and deliver a best-in-class service offering from immediately after injury or illness and for the rest of their lives.

The group's services include the Major Trauma Signposting Partnership service inside NHS Major Trauma Centres, expert witness, costs, tax and forensic accountancy, independent financial advice, investment management, and care and case management.

The Group's discretionary fund manager, Ascencia, manages financial portfolios for clients in unique circumstances, often who have received a financial settlement after litigation. In recent years Ascencia has diversified its portfolios to include a Sharia-law-compliant portfolio and a number of ESG portfolios in response to increased interest in socially responsible investing (SRI).

Frenkel Topping has earned a reputation for commercial astuteness underpinned by a strong moral obligation to its clients, employees and wider society, with a continued focus on its Environmental, Social and Governance (ESG) impact.

For more information visit: www.frenkeltoppinggroup.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR FFFIIADITFIV
Date   Source Headline
23rd Apr 20247:00 amRNSInvestor Presentation via Investor Meet Company
22nd Apr 20247:01 amRNSAcquisition
22nd Apr 20247:00 amRNSFinal Results
12th Mar 20247:00 amRNSNotice of Results
20th Feb 20247:00 amRNSDirectorate Change
24th Jan 20247:00 amRNSTrading Update & New Debt Facility
22nd Dec 20238:00 amRNSHolding(s) in Company
13th Nov 20237:00 amRNSPartnership Programme Grows with New Joint Venture
8th Nov 20234:30 pmRNSDirector/PDMR Shareholding
3rd Nov 20238:30 amRNSHolding(s) in Company
3rd Oct 20237:00 amRNSThe Shares and AJ Bell Media investor event
3rd Oct 20237:00 amRNSAppointment of Strategy & Implementation Director
29th Sep 20237:00 amRNSInterim Results
31st Aug 202310:08 amRNSDirector/PDMR Shareholding
29th Aug 20237:00 amRNSDirector Share Purchase
22nd Aug 20237:00 amRNSTrading Update
31st Jul 20237:00 amRNSFEN Announces Joint Venture with Lime Solicitors
21st Jul 20233:20 pmRNSIssue of consideration shares
6th Jul 20237:00 amRNSFEN announces New Major Trauma Centre
20th Jun 20237:00 amRNSDirector/PDMR Shareholding
14th Jun 202312:20 pmRNSResult of AGM
5th Jun 20237:00 amRNSFEN announces New Major Trauma Centre
15th May 20234:15 pmRNSAnnual Report Posting, Notice of AGM & Dividend
24th Apr 20237:00 amRNSFinal Results
22nd Mar 20234:00 pmRNSHolding(s) in Company
15th Mar 202311:47 amRNSDirector/PDMR Shareholding
8th Mar 20237:00 amRNSInvestor Presentation
13th Feb 20237:00 amRNSFrenkel Topping Partnership Programme Grows
7th Feb 20237:00 amRNSTrading Update and Notice of Results
10th Nov 20222:50 pmRNSInterim Dividend Timetable
3rd Nov 20227:00 amRNSFEN to present at AJ Bell investor webinar
24th Oct 20222:30 pmRNSDirector/PDMR Shareholding and Holdings in Company
24th Oct 202212:15 pmRNSHolding(s) in Company
3rd Oct 20227:00 amRNSDirector/PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
13th Sep 20227:00 amRNSCompletion of Two Acquisitions
31st Aug 20222:15 pmRNSNotice of Results
3rd Aug 202210:17 amRNSHolding(s) in Company
3rd Aug 202210:15 amRNSHolding(s) in Company
29th Jul 202212:15 pmRNSResult of General Meeting
25th Jul 20227:00 amRNSFEN Announces Joint Venture with CFG Law
25th Jul 20227:00 amRNSFEN Announces Joint Venture with CFG Law
12th Jul 202210:50 amRNSHolding(s) in Company
6th Jul 20227:00 amRNSResults of Placing
5th Jul 20222:45 pmRNSProposed Placing to raise approximately £10m
22nd Jun 202211:40 amRNSResult of AGM
16th May 20228:25 amRNSAnnual Report Posting, Notice of AGM & Dividend
4th May 20221:00 pmRNSDirector/PDMR Shareholding
25th Apr 20227:00 amRNSFinal Results
15th Feb 20227:00 amRNSTrading Update and Notice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.